Experimental Drug Brings Fast Relief in Chronic Migraine

This article originally appeared here.
TEV-48125 is a monoclonal antibody against calcitonin gene-related peptide
TEV-48125 is a monoclonal antibody against calcitonin gene-related peptide

(HealthDay News) — An experimental drug -- TEV-48125 -- brings fast relief to patients with debilitating chronic migraines, according to a new study published online June 8 in Neurology.

The new study findings come from a reanalysis of an early trial of TEV-48125. In that study, 261 patients with chronic migraine were randomly assigned to take monthly injections of the drug -- at a higher (900mg) or lower (675/225mg) dose -- or a placebo, for three months.

Related Articles

The original study found that patients on TEV-48125 saw a drop in the number of hours they had headache pain each month. On average, the whole study group had 162 headache hours a month at the start of the study. Three months later, that had dropped by 60 to 67 hours, on average, among patients on the new drug. The new study found that the effects started as early as three days after the higher-dose injection, and seven days after the lower dose.

"To my knowledge, that's the fastest separation ever demonstrated in chronic migraine," lead researcher Marcelo Bigal, M.D., of Teva Pharmaceuticals, the company developing TEV-48125, told HealthDay. So far, Green said, there have been "no significant safety signals" with the drug. In the original study, the most common side effects were pain at the injection site and skin irritation.

Abstract
Full Text

Loading links....